Form 4: COO Emily English Exercises Cartesian Therapeutics Stock Options

Cartesian Therapeutics' Chief Operations Officer, Emily English, exercised 7,500 stock options at $3.30 per share, increasing her direct common stock holdings to 62,726 shares.

Summary

• Emily English, Chief Operations Officer of Cartesian Therapeutics, Inc. (RNAC), exercised stock options on November 28, 2025.
• She acquired 7,500 shares of common stock at an exercise price of $3.30 per share.
• Following this transaction, her direct beneficial ownership of common stock increased to 62,726 shares.
• She now beneficially owns 26,869 derivative securities (stock options) after the exercise.
• The exercised options were fully vested and exercisable, with an expiration date of April 25, 2031.
• These options originated from options to purchase Old Cartesian common stock, which were converted into options for the issuer's common stock during a merger on November 13, 2023.

Sentiment

Score: 6

Explanation: The exercise of stock options by a Chief Operations Officer is a routine insider transaction, indicating the officer is realizing value from their equity compensation. While not a direct 'buy' in the open market, it reflects an insider's continued stake in the company and is generally viewed as a neutral to slightly positive signal.

Positives

• The Chief Operations Officer, Emily English, increased her direct beneficial ownership of common stock by 7,500 shares, demonstrating continued personal investment in the company.
• The exercise of options at a strike price of $3.30 indicates that the options were in-the-money, allowing the officer to realize value from her equity compensation.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider transactions, such as the exercise of stock options, are a common occurrence in publicly traded companies. They typically reflect an executive realizing value from their compensation package and are often pre-arranged under Rule 10b5-1 plans.

Stakeholder Impact

• Shareholders may view the increase in direct shareholdings by a key executive as a minor positive signal of insider confidence in the company's long-term prospects.

Key Dates

Recommendation

This Form 4 filing details a routine exercise of stock options by a company officer. While it shows an insider increasing their direct shareholdings, it does not provide new fundamental information about the company's performance, strategic direction, or valuation to warrant a change in investment recommendation. Investors should consider broader company fundamentals and market conditions before making investment decisions.

Keywords

Cartesian Therapeutics, RNAC, Emily English, Stock Option Exercise, Insider Transaction, Form 4, COO, Equity Compensation